Skip to content
2000
image of Insights into the Molecular Mechanisms of Neurodegenerative Diseases: Exploring Molecular Pathways and the Therapeutic Potential of Rivastigmine

Abstract

Neurodegenerative diseases are characterized by the progressive loss of neuronal function and structure, often leading to motor and cognitive impairments. The intricate molecular mechanisms underlying these diseases involve key pathways such as cholinergic signaling, oxidative stress, amyloid-beta aggregation, tau protein hyperphosphorylation, mitochondrial dysfunction, and neuroinflammation. Rivastigmine, a potent cholinesterase inhibitor, has emerged as a promising therapeutic agent due to its dual inhibitory effects on acetylcholinesterase and butyrylcholinesterase, enhancing cholinergic neurotransmission. This review provides a comprehensive overview of the molecular pathways implicated in neurodegenerative diseases and critically examines the therapeutic potential of Rivastigmine. Emphasis is placed on its mechanism of action, clinical efficacy, and limitations in addressing neurodegeneration. Current advancements, clinical trial outcomes, and potential future directions are discussed to highlight the utility of this approach in the treatment of neurodegenerative disorders.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/0118715273380857251111115119
2026-02-23
2026-03-04

  • From This Site

    /content/journals/cnsnddt/10.2174/0118715273380857251111115119
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Di Gregorio E. Borroni B. Giorgio E. ELOVL5 mutations cause spinocerebellar ataxia 38. Am. J. Hum. Genet. 2014 95 2 209 217 10.1016/j.ajhg.2014.07.001 25065913
    [Google Scholar]
  2. Gaugler J. James B. Johnson T. Scholz K. Weuve J. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016 12 4 459 509 10.1016/j.jalz.2016.03.001 27570871
    [Google Scholar]
  3. Hamer M. Chida Y. Physical activity and risk of neurodegenerative disease: A systematic review of prospective evidence. Psychol. Med. 2009 39 1 3 11 10.1017/S0033291708003681 18570697
    [Google Scholar]
  4. Thies W. Bleiler L. 2011 Alzheimer’s disease facts and figures. Alzheimers Dement. 2011 7 2 208 244 10.1016/j.jalz.2011.02.004 21414557
    [Google Scholar]
  5. Bekris L.M. Mata I.F. Zabetian C.P. The genetics of Parkinson disease. J. Geriatr. Psychiatry Neurol. 2010 23 4 228 242 10.1177/0891988710383572 20938043
    [Google Scholar]
  6. Zuo L. Zhou T. Pannell B.K. Ziegler A.C. Best T.M. Biological and physiological role of reactive oxygen species - The good, the bad and the ugly. Acta Physiol. 2015 214 3 329 348 10.1111/apha.12515 25912260
    [Google Scholar]
  7. He F. Zuo L. Redox roles of reactive oxygen species in cardiovascular diseases. Int. J. Mol. Sci. 2015 16 11 27770 27780 10.3390/ijms161126059 26610475
    [Google Scholar]
  8. Dias V. Junn E. Mouradian M.M. The role of oxidative stress in Parkinson’s disease. J. Parkinsons Dis. 2013 3 4 461 491 10.3233/JPD‑130230 24252804
    [Google Scholar]
  9. Grinberg L.T. Rueb U. Heinsen H. Brainstem: Neglected locus in neurodegenerative diseases. Front. Neurol. 2011 2 42 10.3389/fneur.2011.00042 21808630
    [Google Scholar]
  10. Dugger B.N. Adler C.H. Shill H.A. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat. Disord. 2014 20 5 525 529 10.1016/j.parkreldis.2014.02.012 24637124
    [Google Scholar]
  11. Milenkovic I. Kovacs G.G. Incidental corticobasal degeneration in a 76-year-old woman. Clin. Neuropathol. 2013 32 1 69 72 10.5414/NP300515 23006474
    [Google Scholar]
  12. Martínez-Maldonado A. Luna-Muñoz J. Ferrer I. Incidental corticobasal degeneration. Neuropathol. Appl. Neurobiol. 2016 42 7 659 663 10.1111/nan.12339 27461552
    [Google Scholar]
  13. Tcw J. Goate A.M. Genetics of β-amyloid precursor protein in Alzheimer’s disease. Cold Spring Harb. Perspect. Med. 2017 7 6 a024539 10.1101/cshperspect.a024539 28003277
    [Google Scholar]
  14. Armstrong R.A. What causes alzheimer’s disease? Folia Neuropathol. 2013 51 3 169 188 10.5114/fn.2013.37702 24114635
    [Google Scholar]
  15. Sibille E. Molecular aging of the brain, neuroplasticity, and vulnerability to depression and other brain-related disorders. Dialogues Clin. Neurosci. 2013 15 1 53 65 10.31887/DCNS.2013.15.1/esibille 23576889
    [Google Scholar]
  16. Grossberg G.T. Cholinesterase inhibitors for the treatment of Alzheimer’s disease: Getting on and staying on. Curr. Ther. Res. Clin. Exp. 2003 64 4 216 235 10.1016/S0011‑393X(03)00059‑6 24944370
    [Google Scholar]
  17. Weinstock M. Selectivity of cholinesterase inhibition: Clinical implications for the treatment of Alzheimer’s disease. CNS Drugs 1999 12 4 307 323 10.2165/00023210‑199912040‑00005
    [Google Scholar]
  18. Houldsworth A. Role of oxidative stress in neurodegenerative disorders: A review of reactive oxygen species and prevention by antioxidants. Brain Commun. 2023 6 1 fcad356 10.1093/braincomms/fcad356 38214013
    [Google Scholar]
  19. Gu C. Zhang Q. Li Y. The PI3K/AKT pathway—the potential key mechanisms of traditional chinese medicine for stroke. Front. Med. 2022 9 May 900809 10.3389/fmed.2022.900809 35712089
    [Google Scholar]
  20. Liu S. Han S. Dai Q. Li S. Li J. BICAO-induced ischaemia caused depressive-like behaviours and caspase-8/-9-dependent brain regional neural cell apoptosis in mice. Stroke Vasc. Neurol. 2018 3 1 1 8 10.1136/svn‑2017‑000109 29600001
    [Google Scholar]
  21. Wang X. Zhou Y. Gao Q. The role of exosomal microRNAs and oxidative stress in neurodegenerative diseases. Oxid. Med. Cell. Longev. 2020 2020 1 17 10.1155/2020/3232869 33193999
    [Google Scholar]
  22. Mondini L. Noorani A. Pagnotta M.A. Assessing plant genetic diversity by molecular tools. Diversity 2009 1 1 19 35 10.3390/d1010019
    [Google Scholar]
  23. Rahman M.M. Islam M.R. Yamin M. Islam M.M. Sarker M.T. Meem A.F.K. Emerging role of neuron-glia in neurological disorders: At a glance. Oxid. Med. Cell. Longev. 2022 3201644 10.1155/2022/3201644 36046684
    [Google Scholar]
  24. Wang H. Devadoss D. Nair M. Chand H.S. Lakshmana M.K. Novel Alzheimer risk factor IQ motif containing protein K is abundantly expressed in the brain and is markedly increased in patients with Alzheimer’s disease. Front. Cell. Neurosci. 2022 16 Jul 954071 10.3389/fncel.2022.954071 35928571
    [Google Scholar]
  25. Ertuzun T. Semerci A. Cakir M.E. Investigation of base excision repair gene variants in late-onset Alzheimer’s disease. PLoS One 2019 14 8 0221362 10.1371/journal.pone.0221362 31415677
    [Google Scholar]
  26. Chang D. Nalls M.A. Hallgrímsdóttir I.B. A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat. Genet. 2017 49 10 1511 1516 10.1038/ng.3955 28892059
    [Google Scholar]
  27. Correia K. Harold D. Kim K.H. The genetic modifiers of motor onsetAge (GeM MOA) website: Genome-wide association analysis for genetic modifiers of Huntington’s disease. J. Huntingtons Dis. 2015 4 3 279 284 10.3233/JHD‑150169 26444025
    [Google Scholar]
  28. van’t Spijker H.M. Almeida S. How villains are made: The translation of dipeptide repeat proteins in C9ORF72-ALS/FTD. Gene 2023 858 Mar 147167 10.1016/j.gene.2023.147167 36621656
    [Google Scholar]
  29. Rõlova T. Lehtonen Š. Goldsteins G. Kettunen P. Koistinaho J. Metabolic and immune dysfunction of glia in neurodegenerative disorders: Focus on iPSC models. Stem Cells 2021 39 3 256 265 10.1002/stem.3309 33270954
    [Google Scholar]
  30. Lee D.S.W. Rojas O.L. Gommerman J.L. B cell depletion therapies in autoimmune disease: Advances and mechanistic insights. Nat. Rev. Drug Discov. 2021 20 3 179 199 10.1038/s41573‑020‑00092‑2 33324003
    [Google Scholar]
  31. Twohig D. Nielsen H.M. α-synuclein in the pathophysiology of Alzheimer’s disease. Mol. Neurodegener. 2019 14 1 23 10.1186/s13024‑019‑0320‑x 31186026
    [Google Scholar]
  32. Bertolotti A. Importance of the subcellular location of protein deposits in neurodegenerative diseases. Curr. Opin. Neurobiol. 2018 51 127 133 10.1016/j.conb.2018.03.004 29631171
    [Google Scholar]
  33. Bae E.J. Ho D.H. Park E. Lipid peroxidation product 4-hydroxy-2-nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of α-synuclein. Antioxid. Redox Signal. 2013 18 7 770 783 10.1089/ars.2011.4429 22867050
    [Google Scholar]
  34. Kumar V. Sami N. Kashav T. Islam A. Ahmad F. Hassan M.I. Protein aggregation and neurodegenerative diseases: From theory to therapy. Eur. J. Med. Chem. 2016 124 1105 1120 10.1016/j.ejmech.2016.07.054 27486076
    [Google Scholar]
  35. Takalo M. Salminen A. Soininen H. Hiltunen M. Haapasalo A. Protein aggregation and degradation mechanisms in neurodegenerative diseases. Am. J. Neurodegener. Dis. 2013 2 1 1 14 23516262
    [Google Scholar]
  36. Wang Y. Cai M. Lou Y. Zhang S. Liu X. ZBTB20-AS1 promoted Alzheimer’s disease progression through ZBTB20/GSK-3β/Tau pathway. Biochem. Biophys. Res. Commun. 2023 640 88 96 10.1016/j.bbrc.2022.11.107 36502636
    [Google Scholar]
  37. Göbel B. Oltmanns K.M. Chung M. Linking neuronal brain activity to the glucose metabolism. Theor. Biol. Med. Model. 2013 10 1 50 10.1186/1742‑4682‑10‑50 23988084
    [Google Scholar]
  38. Annesley S.J. Fisher P.R. Mitochondria in health and disease. Cells 2019 8 7 680 10.3390/cells8070680 31284394
    [Google Scholar]
  39. Bader V. Winklhofer K.F. Mitochondria at the interface between neurodegeneration and neuroinflammation. Semin. Cell Dev. Biol. 2020 99 163 171 10.1016/j.semcdb.2019.05.028 31154011
    [Google Scholar]
  40. Ross C.A. Truant R. A unifying mechanism in neurodegeneration. Nature 2017 541 7635 34 35 10.1038/nature21107 28002410
    [Google Scholar]
  41. Wilkins H.M. Weidling I.W. Ji Y. Swerdlow R.H. Mitochondria-derived damage-associated molecular patterns in neurodegeneration. Front. Immunol. 2017 8 APR 508 10.3389/fimmu.2017.00508 28491064
    [Google Scholar]
  42. Wiseman F.K. Al-Janabi T. Hardy J. A genetic cause of Alzheimer disease: Mechanistic insights from Down syndrome. Nat. Rev. Neurosci. 2015 16 9 564 574 10.1038/nrn3983 26243569
    [Google Scholar]
  43. Bastiat G. Plourde F. Motulsky A. Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer’s disease. Biomaterials 2010 31 23 6031 6038 10.1016/j.biomaterials.2010.04.009 20472283
    [Google Scholar]
  44. Jann M.W. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy 2000 20 1 1 12 10.1592/phco.20.1.1.34664 10641971
    [Google Scholar]
  45. Müller T. Rivastigmine in the treatment of patients with Alzheimer’s disease. Neuropsychiatr. Dis. Treat. 2007 3 2 211 218 10.2147/nedt.2007.3.2.211 19300554
    [Google Scholar]
  46. Nordberg A Ballard C Bullock R Darreh-Shori T Somogyi M. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease. Prim Care Companion CNS Disord 2013 15 2 PCC.12r01412. 10.4088/PCC.12r01412 23930233
    [Google Scholar]
  47. Islam M.T. Aktaruzzaman M. Barai C. In silico screening of naturally derived dietary compounds as potential butyrylcholinesterase inhibitors for Alzheimer’s disease treatment. Sci. Rep. 2025 15 1 17134 10.1038/s41598‑025‑98092‑y 40382441
    [Google Scholar]
  48. Perry E.K. Perry R.H. Blessed G. Tomlinson B.E. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol. 1978 4 4 273 277 10.1111/j.1365‑2990.1978.tb00545.x 703927
    [Google Scholar]
  49. Hossain M. Jhee S.S. Shiovitz T. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer’s type. Clin. Pharmacokinet. 2002 41 3 225 234 10.2165/00003088‑200241030‑00006 11929322
    [Google Scholar]
  50. Tan E.C.K. Hilmer S.N. Garcia-Ptacek S. Bell J.S. Current approaches to the pharmacological treatment of Alzheimer’s disease. Aust. J. Gen. Pract. 2018 47 9 586 592 10.31128/AJGP‑05‑18‑4586 30244564
    [Google Scholar]
  51. Moreira N.C.S. Lima J.E.B.F. Marchiori M.F. Carvalho I. Sakamoto-Hojo E.T. Neuroprotective effects of cholinesterase inhibitors: Current scenario in therapies for Alzheimer’s disease and future perspectives. J. Alzheimers Dis. Rep. 2022 6 1 177 193 10.3233/ADR‑210061 35591949
    [Google Scholar]
  52. Andin J. Enz A. Gentsch C. Marcusson J. Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression. Dement. Geriatr. Cogn. Disord. 2005 19 1 18 23 10.1159/000080966 15383741
    [Google Scholar]
  53. Pozzi F.E. Conti E. Appollonio I. Ferrarese C. Tremolizzo L. Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review. Front. Neurosci. 2022 16 998224 10.3389/fnins.2022.998224 36203811
    [Google Scholar]
  54. Giacobini E. Spiegel R. Enz A. Veroff A.E. Cutler N.R. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: Correlation with cognitive benefit. J. Neural Transm. 2002 109 7-8 1053 1065 10.1007/s007020200089 12111443
    [Google Scholar]
  55. Mesulam M.M. Guillozet A. Shaw P. Levey A. Duysen E.G. Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002 110 4 627 639 10.1016/S0306‑4522(01)00613‑3 11934471
    [Google Scholar]
  56. Zhang H. Wei W. Zhao M. Interaction between Aβ and tau in the pathogenesis of Alzheimer’s disease. Int. J. Biol. Sci. 2021 17 9 2181 2192 10.7150/ijbs.57078 34239348
    [Google Scholar]
  57. Holmes C. Ballard C. Lehmann D. Rate of progression of cognitive decline in Alzheimer’s disease: Effect of butyrylcholinesterase K gene variation. J. Neurol. Neurosurg. Psychiatry 2005 76 5 640 643 10.1136/jnnp.2004.039321 15834019
    [Google Scholar]
  58. McGuire M.C. Nogueira C.P. Bartels C.F. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc. Natl. Acad. Sci. USA 1989 86 3 953 957 10.1073/pnas.86.3.953 2915989
    [Google Scholar]
  59. Darreh-Shori T. Almkvist O. Guan Z.Z. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002 59 4 563 572 10.1212/WNL.59.4.563 12196650
    [Google Scholar]
  60. Lane R.M. Kivipelto M. Greig N.H. Acetylcholinesterase and its inhibition in Alzheimer disease. Clin. Neuropharmacol. 2004 27 3 141 149 10.1097/00002826‑200405000‑00011 15190239
    [Google Scholar]
  61. Bailey J.A. Ray B. Greig N.H. Lahiri D.K. Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 2011 6 7 21954 10.1371/journal.pone.0021954 21799757
    [Google Scholar]
  62. Habib A. Sawmiller D. Tan J. Restoring sAPPα functions as a potential treatment for Alzheimer’s disease. J. Neurosci. Res. 2016 95 4 973 10.1002/jnr.23823 27531392
    [Google Scholar]
  63. Liu X. Liu Y. Ji S. Secretases related to amyloid precursor protein processing. Membranes 2021 11 12 983 10.3390/membranes11120983 34940484
    [Google Scholar]
  64. Shan L. Zhang T. Fan K. Cai W. Liu H. Astrocyte-neuron signaling in synaptogenesis. Front. Cell Dev. Biol. 2021 9 Jul 680301 10.3389/fcell.2021.680301 34277621
    [Google Scholar]
  65. Elsworthy R.J. Dunleavy C. Whitham M. Aldred S. Exercise for the prevention of Alzheimer’s disease: Multiple pathways to promote non-amyloidogenic AβPP processing. Aging Health Res 2022 2 3 100093 10.1016/j.ahr.2022.100093
    [Google Scholar]
  66. Sadleir K.R. Kandalepas P.C. Buggia-Prévot V. Nicholson D.A. Thinakaran G. Vassar R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer’s disease. Acta Neuropathol. 2016 132 2 235 256 10.1007/s00401‑016‑1558‑9 26993139
    [Google Scholar]
  67. Greig N.H. Lahiri D.K. Kumar S. Butyrylcholinesterase: An important new target in Alzheimer’s disease therapy. Int. Psychogeriatr. 2002 14 Suppl. 1 77 91 10.1017/S1041610203008676 12636181
    [Google Scholar]
  68. Billington C.K. Penn R.B. Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respir. Res. 2003 4 1 2 10.1186/rr195 12648290
    [Google Scholar]
  69. Predescu D.V. Crețoiu S.M. Crețoiu D. G protein-coupled receptors (GPCRs)-Mediated calcium signaling in ovarian cancer: Focus on GPCRs activated by neurotransmitters and inflammation-associated molecules. Int. J. Mol. Sci. 2019 20 22 5568 10.3390/ijms20225568 31703453
    [Google Scholar]
  70. Mori M.X. Itsuki K. Hase H. Dynamics of receptor-operated Ca2+ currents through TRPC channels controlled via the PI(4,5)P2-PLC signaling pathway. Front. Pharmacol. 2015 6 FEB 22 10.3389/fphar.2015.00022 25717302
    [Google Scholar]
  71. Kankanamge D. Ubeysinghe S. Tennakoon M. Dissociation of the G protein βγ from the Gq-PLCβ complex partially attenuates PIP2 hydrolysis. J. Biol. Chem. 2021 296 100702 10.1016/j.jbc.2021.100702 33901492
    [Google Scholar]
  72. Ray B. Maloney B. Sambamurti K. Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease. Transl. Psychiatry 2020 10 1 47 10.1038/s41398‑020‑0709‑x 32066688
    [Google Scholar]
  73. Bullock R. Touchon J. Bergman H. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr. Med. Res. Opin. 2005 21 8 1317 1327 10.1185/030079905X56565 16083542
    [Google Scholar]
  74. Potkin S.G. Anand R. Fleming K. Brain metabolic and clinical effects of rivastigmine in Alzheimer’s disease. Int. J. Neuropsychopharmacol. 2001 4 3 223 230 10.1017/S1461145701002528 11602028
    [Google Scholar]
  75. Richter N. Beckers N. Onur O.A. Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease. Brain 2018 141 3 903 915 10.1093/brain/awx356 29309600
    [Google Scholar]
  76. Modrego P.J. Pina M.A. Fayed N. Díaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer’s disease: A nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 2006 20 10 867 877 10.2165/00023210‑200620100‑00006 16999455
    [Google Scholar]
  77. Reid A.T. Evans A.C. Structural networks in Alzheimer’s disease. Eur. Neuropsychopharmacol. 2013 23 1 63 77 10.1016/j.euroneuro.2012.11.010 23294972
    [Google Scholar]
  78. Bejar C. Wang R.H. Weinstock M. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur. J. Pharmacol. 1999 383 3 231 240 10.1016/S0014‑2999(99)00643‑3 10594314
    [Google Scholar]
  79. Nizri E. Irony-Tur-Sinai M. Faranesh N. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J. Neuroimmunol. 2008 203 1 12 22 10.1016/j.jneuroim.2008.06.018 18692909
    [Google Scholar]
  80. Mosconi L. Pupi A. De Leon M.J. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease. Ann. N. Y. Acad. Sci. 2008 1147 1 180 195 10.1196/annals.1427.007 19076441
    [Google Scholar]
  81. Terry R.D. Masliah E. Salmon D.P. Physical basis of cognitive alterations in alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991 30 4 572 580 10.1002/ana.410300410 1789684
    [Google Scholar]
  82. Sonali N. Tripathi M. Sagar R. Velpandian T. Subbiah V. Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer’s patients. CNS Neurosci. Ther. 2013 19 2 91 97 10.1111/cns.12036 23206182
    [Google Scholar]
  83. Devineni D. Klein-Szanto A. Gallo J.M. Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. J. Neurooncol. 1995 24 2 143 152 10.1007/BF01078484 7562001
    [Google Scholar]
  84. Vahid Z.F. Eskandani M. Dadashi H. Vandghanooni S. Rashidi M.R. Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer’s disease. Heliyon 2024 10 23 40756 10.1016/j.heliyon.2024.e40756 39717593
    [Google Scholar]
  85. Eldufani J. Blaise G. The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications. Alzheimers Dement. 2019 5 1 175 183 10.1016/j.trci.2019.03.004 31194017
    [Google Scholar]
  86. Fortea J. Ferrer-Picón E. An overview of the rivastigmine 13.3 mg/24h transdermal patch as a treatment option for Alzheimer’s disease. Expert Rev. Neurother. 2025 10.1080/14737175.2025.2527211
    [Google Scholar]
  87. Moretti D.V. Frisoni G.B. Binetti G. Zanetti O. Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease. Front. Aging Neurosci. 2014 6 179 10.3389/fnagi.2014.00179 25100996
    [Google Scholar]
  88. Farlow M.R. Grossberg G.T. Sadowsky C.H. Meng X. Velting D.M. A 24-week, open-label extension study to investigate the long-term safety, tolerability, and efficacy of 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2015 29 2 110 116 10.1097/WAD.0000000000000073 25437301
    [Google Scholar]
  89. Mamikonyan E. Xie S.X. Melvin E. Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study. Mov. Disord. 2015 30 7 912 918 10.1002/mds.26236 25914281
    [Google Scholar]
  90. McDonald J. Pourcher E. Nadeau A. Corbeil P. A randomized trial of oral and transdermal rivastigmine for postural instability in Parkinson disease dementia. Clin. Neuropharmacol. 2018 41 3 87 93 10.1097/WNF.0000000000000275 29537978
    [Google Scholar]
  91. Madson K.A. Brown S. Rivastigmine: Dementia with lewy bodies. Hosp. Pharm. 2016 51 2 129 131 10.1310/hpj5102‑129 38746766
    [Google Scholar]
  92. Terzaghi M. Rustioni V. Manni R. Pacchetti C. Zangaglia R. Ossola M. Agrypnia with nocturnal confusional behaviors in dementia with Lewy bodies: Immediate efficacy of rivastigmine. Mov. Disord. 2010 25 5 647 649 10.1002/mds.22726 20175184
    [Google Scholar]
  93. Onor M.L. Trevisiol M. Aguglia E. Rivastigmine in the treatment of Alzheimer’s disease: An update. Clin. Interv. Aging 2007 2 1 17 32 10.2147/ciia.2007.2.1.17 18044073
    [Google Scholar]
  94. Cummings J.L. Koumaras B. Chen M. Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: A 26-week, multicenter, open-label study. Am. J. Geriatr. Pharmacother. 2005 3 3 137 148 10.1016/S1543‑5946(05)80020‑0 16257816
    [Google Scholar]
  95. Aupperle P.M. Koumaras B. Chen M. Rabinowicz A. Mirski D. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer’s disease: Results of a 52-week open-label study. Curr. Med. Res. Opin. 2004 20 10 1605 1612 10.1185/030079904125004204 15462693
    [Google Scholar]
  96. Webster L. Costafreda Gonzalez S. Stringer A. Measuring the prevalence of sleep disturbances in people with dementia living in care homes: A systematic review and meta-analysis. Sleep 2020 43 4 zsz251 10.1093/sleep/zsz251 31633188
    [Google Scholar]
  97. Farlow M.R. Lilly M.L. Rivastigmine: An open-label, observational study of safety and effectiveness in treating patients with Alzheimer’s disease for up to 5 years. BMC Geriatr. 2005 5 1 3 10.1186/1471‑2318‑5‑3 15659242
    [Google Scholar]
  98. Lin P. Sun J. Cheng Q. Yang Y. Cordato D. Gao J. The development of pharmacological therapies for Alzheimer’s disease. Neurol. Ther. 2021 10 2 609 626 10.1007/s40120‑021‑00282‑z 34532845
    [Google Scholar]
  99. Rombouts S A RB. Barkhof F. Van Meel C.S. Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 2002 73 6 665 671 10.1136/jnnp.73.6.665 12438467
    [Google Scholar]
  100. Kennedy J.S. Polinsky R.J. Johnson B. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J. Clin. Psychopharmacol. 1999 19 6 513 521 10.1097/00004714‑199912000‑00005 10587286
    [Google Scholar]
  101. Nordberg A. Darreh-Shori T. Peskind E. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr. Alzheimer Res. 2009 6 1 4 14 10.2174/156720509787313961 19199870
    [Google Scholar]
  102. Zhang J. Cheng J. Yang H. Effects of rivastigmine on brain functional networks in patients with Alzheimer disease based on the graph theory. Clin. Neuropharmacol. 2021 44 1 9 16 10.1097/WNF.0000000000000427 33337622
    [Google Scholar]
  103. Reingold J.L. Morgan J.C. Sethi K.D. Rivastigmine for the treatment of dementia associated with Parkinson’s disease. Neuropsychiatr. Dis. Treat. 2007 3 6 775 783 10.2147/ndt.s1134 19300613
    [Google Scholar]
  104. Guo Q. Thabane L. Hall G. McKinnon M. Goeree R. Pullenayegum E. A systematic review of the reporting of sample size calculations and corresponding data components in observational functional magnetic resonance imaging studies. Neuroimage 2014 86 172 181 10.1016/j.neuroimage.2013.08.012 23954487
    [Google Scholar]
  105. Birks J.S. Harvey R.J. Donepezil for dementia due to Alzheimer’s disease. Cochrane Libr. 2018 2018 6 CD001190 10.1002/14651858.CD001190.pub3 29923184
    [Google Scholar]
  106. Emre M. Aarsland D. Albanese A. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med. 2004 351 24 2509 2518 10.1056/NEJMoa041470 15590953
    [Google Scholar]
  107. Cummings J. Froelich L. Black S.E. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2012 33 5 341 353 10.1159/000340056 22796905
    [Google Scholar]
  108. Crofts A. Trotman-Lucas M. Janus J. Kelly M. Gibson C.L. A longitudinal, multi-parametric functional MRI study to determine age-related changes in the rodent brain. Neuroimage 2020 218 116976 10.1016/j.neuroimage.2020.116976 32464290
    [Google Scholar]
  109. Kobayashi H. Ohnishi T. Nakagawa R. Yoshizawa K. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild‐to‐moderate Alzheimer’s disease: A Bayesian network meta‐analysis. Int. J. Geriatr. Psychiatry 2016 31 8 892 904 10.1002/gps.4405 26680338
    [Google Scholar]
  110. Shaw K.T.Y. Utsuki T. Rogers J. Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. USA 2001 98 13 7605 7610 10.1073/pnas.131152998 11404470
    [Google Scholar]
  111. Maccecchini M.L. Chang M.Y. Pan C. John V. Zetterberg H. Greig N.H. Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: Target engagement, tolerability and pharmacokinetics in humans. J. Neurol. Neurosurg. Psychiatry 2012 83 9 894 902 10.1136/jnnp‑2012‑302589 22791904
    [Google Scholar]
  112. Takada-Takatori Y. Nakagawa S. Kimata R. Donepezil modulates amyloid precursor protein endocytosis and reduction by up-regulation of SNX33 expression in primary cortical neurons. Sci. Rep. 2019 9 1 11922 10.1038/s41598‑019‑47462‑4 31417133
    [Google Scholar]
  113. Mohamed L.A. Keller J.N. Kaddoumi A. Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer’s disease mouse model. Biochim. Biophys. Acta Mol. Basis Dis. 2016 1862 4 778 787 10.1016/j.bbadis.2016.01.013 26780497
    [Google Scholar]
  114. Lahiri D.K. Farlow M.R. Nurnberger J.I. Greig N.H. Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann. N. Y. Acad. Sci. 1997 826 1 416 421 10.1111/j.1749‑6632.1997.tb48495.x 9329715
    [Google Scholar]
  115. Lahiri D.K. Farlow M.R. Differential effect of tacrine and physostigmine on the secretion of the β-amyloid precursor protein in cell lines. J. Mol. Neurosci. 1996 7 1 41 49 10.1007/BF02736847 8835781
    [Google Scholar]
  116. Venti A. Giordano T. Eder P. The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5′-untranslated region. Ann. N. Y. Acad. Sci. 2004 1035 1 34 48 10.1196/annals.1332.003 15681799
    [Google Scholar]
  117. Youdim M.B.H. Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell. Mol. Neurobiol. 2001 21 6 555 573 10.1023/A:1015131516649 12043833
    [Google Scholar]
  118. Yogev-Falach M. Amit T. Bar-Am O. Weinstock M. Youdim M.B.H. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 2002 16 12 1674 1676 10.1096/fj.02‑0198fje 12206996
    [Google Scholar]
  119. Mandel S.A. Amit T. Weinreb O. Reznichenko L. Youdim M.B.H. Simultaneous manipulation of multiple brain targets by green tea catechins: A potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci. Ther. 2008 14 4 352 365 10.1111/j.1755‑5949.2008.00060.x 19040558
    [Google Scholar]
  120. Hansen R.A. Gartlehner G. Webb A.P. Morgan L.C. Moore C.G. Jonas D.E. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clin. Interv. Aging 2008 3 2 211 225 18686744
    [Google Scholar]
  121. Siddique Y.H. Naz F. Rahul, Varshney H. Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer’s disease. Curr Res Pharmacol Drug Discov 2022 3 100120 10.1016/j.crphar.2022.100120 35992376
    [Google Scholar]
  122. Abbas Raja A. Amjad A. Choudhary A. Comparative effectiveness of rivastigmine and donepezil in patients with Alzheimer’s disease: A retrospective cohort study. Cureus 2025 17 5 83498 10.7759/cureus.83498 40470403
    [Google Scholar]
  123. Khoury R. Rajamanickam J. Grossberg G.T. An update on the safety of current therapies for Alzheimer’s disease: Focus on rivastigmine. Ther. Adv. Drug Saf. 2018 9 3 171 178 10.1177/2042098617750555 29492246
    [Google Scholar]
  124. Kandiah N. Pai M.C. Senanarong V. Rivastigmine: The advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia. Clin. Interv. Aging 2017 12 697 707 10.2147/CIA.S129145 28458525
    [Google Scholar]
  125. Emre M. Bernabei R. Blesa R. Drug profile: Transdermal rivastigmine patch in the treatment of Alzheimer disease. CNS Neurosci. Ther. 2010 16 4 246 253 10.1111/j.1755‑5949.2010.00141.x 20370805
    [Google Scholar]
  126. Bird D. Ravindra N.M. Transdermal drug delivery and patches—An overview. Med. Devices Sensor 2020 3 6 e10069 10.1002/mds3.10069
    [Google Scholar]
  127. Breijyeh Z. Karaman R. 2020 Available from: https://www.mdpi.com/1420-3049/25/24/5789/htm
  128. Bhattacharjee S Patanwala AE Lo-Ciganic WH Malone DC Lee JK Knapp SM Alzheimer’s disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study 2019 Available from: https://www.sciencedirect.com/science/article/pii/S2352873719300253. 10.1016/j.trci.2019.05.005
  129. Adler G. Mueller B. Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer’s disease under daily practice conditions. Int. J. Clin. Pract. 2014 68 4 465 470 10.1111/ijcp.12374 24588972
    [Google Scholar]
  130. Clegg A. Bryant J. Nicholson T. McIntyre L. De Broe S. Gerard K. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: A rapid and systematic review. Health Technol. Assess. 2001 5 1 1 137 10.3310/hta5010 11262420
    [Google Scholar]
  131. Blanco-Silvente L. Castells X. Saez M. Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer’s Disease: A Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients. Int. J. Neuropsychopharmacol. 2017 20 7 519 528 10.1093/ijnp/pyx012 28201726
    [Google Scholar]
  132. Shah B. Khunt D. Bhatt H. Misra M. Padh H. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters. Eur. J. Pharm. Sci. 2015 78 54 66 10.1016/j.ejps.2015.07.002 26143262
    [Google Scholar]
  133. Al Asmari A.K. Ullah Z. Tariq M. Fatani A. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des. Devel. Ther. 2016 10 205 215 26834457
    [Google Scholar]
  134. Chauhan M.K. Sharma P.K. Optimization and characterization of rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia. Chem. Phys. Lipids 2019 224 Nov 104794 10.1016/j.chemphyslip.2019.104794 31361985
    [Google Scholar]
  135. Yang Z.Z. Zhang Y.Q. Wang Z.Z. Wu K. Lou J.N. Qi X.R. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int. J. Pharm. 2013 452 1-2 344 354 10.1016/j.ijpharm.2013.05.009 23680731
    [Google Scholar]
  136. Zielińska A. Carreiró F. Oliveira A.M. Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules 2020 25 16 3731 10.3390/molecules25163731 32824172
    [Google Scholar]
  137. Pagar K. Vavia P. Rivastigmine-loaded L-lactide-depsipeptide polymeric nanoparticles: Decisive formulation variable optimization. Sci. Pharm. 2013 81 3 865 885 10.3797/scipharm.1211‑20 24106679
    [Google Scholar]
  138. Guo H. Wang G. Zhai Z. Rivastigmine nasal spray for the treatment of Alzheimer’s Disease: Olfactory deposition and brain delivery. Int. J. Pharm. 2024 652 Mar 123809 10.1016/j.ijpharm.2024.123809 38224760
    [Google Scholar]
  139. Amft M. Ortner M. Eichenlaub U. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. Alzheimers Res. Ther. 2022 14 1 60 Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9044878/ 10.1186/s13195‑022‑01003‑w 35473631
    [Google Scholar]
  140. Salomone S. Caraci F. Leggio G.M. Fedotova J. Drago F. New pharmacological strategies for treatment of Alzheimer’s disease: Focus on disease modifying drugs. Br. J. Clin. Pharmacol. 2012 73 4 504 517 10.1111/j.1365‑2125.2011.04134.x 22035455
    [Google Scholar]
  141. Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2006 20 2 Suppl. 1 S12 S18 10.1097/01.wad.0000213804.59187.2d 16772751
    [Google Scholar]
  142. Ferris S. Lane R. Sfikas N. Winblad B. Farlow M. Feldman H.H. Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. Gend. Med. 2009 6 2 345 355 10.1016/j.genm.2009.06.004 19682661
    [Google Scholar]
  143. Farlow M. Potkin S. Koumaras B. Veach J. Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch. Neurol. 2003 60 6 843 848 10.1001/archneur.60.6.843 12810489
    [Google Scholar]
  144. Sperling R.A. Aisen P.S. Beckett L.A. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 7 3 280 292 10.1016/j.jalz.2011.03.003 21514248
    [Google Scholar]
  145. Annicchiarico R. Federici A. Pettenati C. Caltagirone C. Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life. Ther. Clin. Risk Manag. 2007 3 6 1113 1123 Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2387294 18516265
    [Google Scholar]
  146. Mattes RD Rowe SB Ohlhorst SD Valuing the Diversity of Research Methods to Advance Nutrition Science. Adv Nutr 2022 13 4 1324 93 Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9340992/. 10.1093/advances/nmac043 35802522
    [Google Scholar]
  147. Abed SS Hamdan FB Hussein MM Al-Mayah QS Plasma tau and neurofilament light chain as biomarkers of Alzheimer’s disease and their relation to cognitive functions. J Med Life. 2023 16 2 284 9 Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10015560/. 10.25122/jml‑2022‑0251 36937471
    [Google Scholar]
  148. Fujita K. Kimura T. Yamakawa A. Genetic background and multidomain interventions in mild cognitive impairment. Alzheimers Res. Ther. 2025 17 1 130 Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12150445/ 10.1186/s13195‑025‑01764‑0 40490801
    [Google Scholar]
  149. Soni U. Singh K. Jain D. Pujari R. Exploring Alzheimer’s disease treatment: Established therapies and novel strategies for future care. Eur. J. Pharmacol. 2025 998 177520 Available from: https://www.sciencedirect.com/science/article/abs/pii/S0014299925002742 10.1016/j.ejphar.2025.177520 40097131
    [Google Scholar]
  150. Singh K. Gupta J.K. Lakhchora G. Advance nanotechnology-based drug delivery systems for Alzheimer’s disease: Advancements and Future Perspectives. Curr. Alzheimer Res. 2025 22 5 327 343 Available from: https://pubmed.ncbi.nlm.nih.gov/40491368/ 40491368
    [Google Scholar]
  151. Congdon E.E. Sigurdsson E.M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 2018 14 7 399 415 Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6463489/ 10.1038/s41582‑018‑0013‑z 29895964
    [Google Scholar]
  152. Kamila P Kar K Chowdhury S Chakraborty P Dutta RSS Effect of neuroinflammation on the progression of Alzheimer’s disease and its significant ramifications for novel anti-inflammatory treatments 2025 Available from: https://www.sciencedirect.com/science/article/pii/S2667242125000715. 10.1016/j.ibneur.2025.05.005
  153. Napolitano G Fasciolo G Venditti P. Mitochondrial Management of Reactive Oxygen Species. Antioxidants 2021 10 11 1824 https://pmc.ncbi.nlm.nih.gov/articles/PMC8614740/. 10.3390/antiox10111824 34829696
    [Google Scholar]
  154. Kalia LV Kalia SK Salter MW NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008 7 8 742 55 Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3589564/ 10.1016/S1474‑4422(08)70165‑0 18635022
    [Google Scholar]
  155. Cantara S. Simoncelli G. Ricci C. Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade. Int. J. Mol. Sci. 2024 25 9 4809 Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11083842/ 10.3390/ijms25094809 38732027
    [Google Scholar]
  156. Rahimi Darehbagh R Seyedoshohadaei SA Ramezani R Rezaei N Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives. Eur J Med Res. 2024 29 1 386 Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11270957/ 10.1186/s40001‑024‑01987‑1 39054501
    [Google Scholar]
  157. Kumar S. Malviya R. Sundram S. 2024 Available from: https://www.sciencedirect.com/science/article/pii/S266614972300049X
/content/journals/cnsnddt/10.2174/0118715273380857251111115119
Loading
Insights into the Molecular Mechanisms of Neurodegenerative Diseases: Exploring Molecular Pathways and the Therapeutic Potential of Rivastigmine
Bentham Science Publishers ; https://doi.org/10.2174/0118715273380857251111115119
/content/journals/cnsnddt/10.2174/0118715273380857251111115119
/content/journals/cnsnddt/10.2174/0118715273380857251111115119
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keywords: cholinesterase inhibitors ; tau protein ; neuroinflammation ; oxidative stress ; amyloid-β ; Alzheimer's disease ; molecular pathways ; Rivastigmine ; Neurodegenerative diseases ; Parkinson's disease

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test